ERBB2 and breast cancer: In conclusion, our study supports that treatment with T-DM1 as well as pertuzumab in combination with trastuzumab and docetaxel, currently is the best targeted drug regimen for HER2+ breast cancer in terms of overall survival rate (OSR) and overall response rate (ORR) and with moderate toxicity, especially for HER2+ advanced or metastatic breast cancer.